Canthera Therapeutics

Canthera Therapeutics is an Australian clinical-stage drug development company primarily focused on oncology and inflammation. Formerly known as Noxopharm, the company is advancing its lead candidate, Veyonda (idronoxil), which acts as a dual-acting sphingosine kinase inhibitor and radio-sensitizer for various solid tumors. Their pipeline includes programs targeting pancreatic cancer and soft tissue sarcoma, as well as a proprietary mRNA vaccine enhancer platform called Sof-Vac. Canthera aims to improve the effectiveness of existing cancer treatments like radiotherapy and chemotherapy while developing novel therapies for high-unmet-need diseases. The company is listed on the Australian Securities Exchange and maintains active research collaborations with leading Australian medical institutes.